Human clinical data limited to case reports and small trials, not large controlled studies
A nice little summary table of important preclinical results helps bridge specific doses, models, and endpoints to a handy reference
They are small versions of proteins
6 There is a need to clarify the potential risk of ophthalmic complications from semaglutide exposure using multicenter data
Do I stop taking it when I hit my goal
Panels show study design (a), higher plasma TMAO (b), worsened IPGTT (c), reduced insulin/C-peptide responses and GSIS under clamp (dk), pancreatic histology (l), altered islet composition by immunostaining (mo), and increased plasma glucagon (p), supporting a mechanistic link between TMAO and -cell dysfunction